For example, sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have recently emerged as an option for reducing the risk of HHF in patients with T2DM and in patients with HF with reduced ejection fraction irrespective of T2DM status.18, 19, 20, 21. The gene discussed is SLC5A2; the disease is hydrops fetalis.